Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs.

Gather and Work Together to Create Advantages
     Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs

As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs, mRNA vaccines, small nucleic acid drugs, PROTAC, and CGT technical service platform that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation for establishing deeper and broader collaborative relationships with global partners.

Binhui Bio has the only fully closed-loop industry-university-research integrated research platform in China for the development of oncolytic virus products - the oncolytic virus (oHSV2) immunotherapy platform.  It collaborates with multiple technology platforms of nucleic acid drugs and protein drugs to develop new Class I biological drugs, and become a pioneer in the collaborative exploration of multi-platform technologies for tumor immunotherapy.  The company's core oncolytic virus product BS001 (OH2 injection) has received NMPA and FDA approval for a total of 5 clinical approvals as a single drug and combination drug, becoming the first in the world to enter clinical research using type Ⅱ herpes simplex virus as a vector and obtain positive efficacy data of oncolytic viruses.  It is also the first major national new drug creation project for oncolytic viruses to enter confirmatory phase III clinical research.

This powerful alliance between the two parties benefits from Medicilon's drug research and development service capabilities accumulated over the years, as well as Binhui Bio's successful experience in the field of new biological drug research and development.  Based on the common vision and goals, both parties will give full play to their respective advantages in technology R&D and market expansion to achieve complementary advantages, effectively utilize resources, expand the market business scale of both parties, and create a professional contract R&D service platform.  Both parties jointly promote the research, development and application of cutting-edge technologies such as oncolytic viruses, nucleic acid drugs and protein drugs.